Last week we sponsored @NTSAD’s Imagine & Believe event to celebrate Dr. Guangping Gao, who was honored for his pioneering research in #genetherapy! We’re very proud to support Dr. Gao and to raise funds to support NTSAD’s mission.

Check out this article in @statnews and learn how our latest #data positions our novel capsids to address ongoing challenges – from narrow therapeutic windows to subsequent toxicity issues – in the #genetherapy space. #biotech #genetherapy #neurology

Today we reported Q3 2022 financial results and provided updates on our corporate and pipeline progress. Read more: $VYGR #biotech #genetherapy #innovation

$VYGR will be hosting a brief Q3 2022 conference call and webcast on Tuesday, November 8th. Mark your calendar and learn more: #biotech #genetherapy #innovation

CEO @Al Sandrock joins genetic medicine company leaders to discuss opportunities for therapeutic development targeting #CNS disorders. For those tuning into @TruistNews Financial Corporation Securities Genetic Medicine #Summit, click here to learn more:

Our Voyagers were once again out in full force on Sunday to support the #ALS community in the annual @WalktoDefeatALS. Learn more about the @alsassociation and how you can support its important mission:

Data from #ESGCT22 supports our efforts to overcome bottlenecks in the #genetherapy space, from capsid delivery to dosing. Learn more about our findings shared at @ESGCT #biotech

Update: @VoyagerTx presents promising Receptor X #data supporting human translation with potential to improve treatment of CNS disease at @ESGCT 29th Annual Congress. Explore the latest receptor and ultra-low dosing data: #genetherapy #ESGCT22

Update: @Pfizer has exercised its option to license a novel, TRACER-generated capsid for a rare neurologic disease target. Learn more here:

Interested in learning about Voyager’s approach to unlocking the potential of AAV gene therapy? Tomorrow, our CEO, Al Sandrock, will be presenting at @Chardan’s 6th Annual #GeneticMedicines Conference. Learn more here: #ChardanGMConf #CGMC2022

Find us at @ESGCT’s 29th Annual Congress where our #AAV Capsid Discovery team will highlight the discovery of a binding receptor for one of our most promising TRACER capsids and more! 

We had the opportunity to prepare toolkits for @SCFG that students will use to learn about crystal structures as part of the organization’s mission to empower the next generation of #womeninSTEM. A huge thanks to SCFG for the visit and our employees for volunteering!

CEO Al Sandrock, joins top industry leaders at @LongwoodLeaders Fall Conference for a discussion on the future of R&D. Join the discussion, register here: #biotech #pharma

Voyager welcomes Todd Carter, Ph.D., as our newly appointed CSO. Learn more about Dr. Carter and his experience in CNS #drugdiscovery: #careers #biotech #genetherapy

Voyager welcomes Peter Pfreundschuh as our newly appointed CFO. Learn more about Pete and his experience: #careers #biotech #genetherapy #Finance

Join us in celebrating our newly expanded leadership team. Together they bring decades of #drugdevelopment experience. Learn more: #careers #biotech #genetherapy

Guided by our mission to deliver breakthroughs in #genetherapy, impassioned by the incredible team of experts that drive innovation every day. Congratulations to our newest Sr. Director of #TechOps, Mahajoub! Explore our open roles 👉

Our CEO Al Sandrock had the opportunity to discuss the promise of #genetherapy and how our science can help bring it to reality with noted biotech investor, @bradlancor: #biotech #research #neuroscience #BTIG

Our quarterly results are in and CEO, Al Sandrock, is sharing details on the recent identification of a receptor for one of our most promising TRACER AAV capsids and more, a significant step toward human translation. View our full Q2 results: #GeneTherapy